Brind.
  1. Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.

GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.

1 report, 1 independent Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.

Who's involved

What this event is mainly about
FDAGSK

How it developed

Newest first. Tap a step to see who reported it.
  1. GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.Sub-event
  2. GSK secured FDA clearance for a lung cancer medicine, adding to its portfolio.1 source

Keep exploring

Part of

Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.

Also in this story

All 4 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped